ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 12.87 Billion KRW | 167.7% |
| 2022 | -12.42 Billion KRW | -136.33% |
| 2021 | 34.19 Billion KRW | 318.75% |
| 2020 | -15.63 Billion KRW | -43.68% |
| 2019 | -10.88 Billion KRW | 44.22% |
| 2018 | -19.5 Billion KRW | -40.68% |
| 2017 | -13.86 Billion KRW | 27.51% |
| 2016 | -19.12 Billion KRW | -535.59% |
| 2015 | -3 Billion KRW | -72.04% |
| 2014 | -1.74 Billion KRW | 81.69% |
| 2013 | -9.55 Billion KRW | -1186.78% |
| 2012 | 878.81 Million KRW | 108.29% |
| 2011 | -10.6 Billion KRW | -360.71% |
| 2010 | 4.06 Billion KRW | 801.26% |
| 2009 | -579.88 Million KRW | 6.9% |
| 2008 | -622.87 Million KRW | 86.33% |
| 2007 | -4.55 Billion KRW | -965.01% |
| 2006 | 526.73 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.78 Billion KRW | -203.87% |
| 2023 Q4 | 6.53 Billion KRW | 2961.76% |
| 2023 Q3 | 213.31 Million KRW | 132.82% |
| 2023 FY | 8.41 Billion KRW | 167.7% |
| 2023 Q1 | 2.31 Billion KRW | 352.85% |
| 2023 Q2 | -649.99 Million KRW | -128.06% |
| 2022 Q2 | 8.68 Billion KRW | 197.36% |
| 2022 FY | -12.42 Billion KRW | -136.33% |
| 2022 Q4 | 511.54 Million KRW | 104.03% |
| 2022 Q3 | -12.69 Billion KRW | -246.16% |
| 2022 Q1 | -8.92 Billion KRW | 0.0% |
| 2021 Q3 | 939.95 Million KRW | 525.21% |
| 2021 FY | 34.19 Billion KRW | 318.75% |
| 2021 Q1 | 2.69 Billion KRW | 126.22% |
| 2021 Q2 | -221.05 Million KRW | -108.22% |
| 2020 Q4 | -10.26 Billion KRW | -351.26% |
| 2020 FY | -15.63 Billion KRW | -43.68% |
| 2020 Q1 | -381.88 Million KRW | 85.84% |
| 2020 Q2 | -9.07 Billion KRW | -2275.91% |
| 2020 Q3 | 4.08 Billion KRW | 145.02% |
| 2019 Q1 | -895.87 Million KRW | 91.74% |
| 2019 FY | -10.88 Billion KRW | 44.22% |
| 2019 Q3 | -894.56 Million KRW | 86.01% |
| 2019 Q2 | -6.39 Billion KRW | -613.62% |
| 2019 Q4 | -2.69 Billion KRW | -201.51% |
| 2018 FY | -19.5 Billion KRW | -40.68% |
| 2018 Q3 | 2.5 Billion KRW | 132.06% |
| 2018 Q4 | -10.84 Billion KRW | -532.45% |
| 2018 Q1 | -3.34 Billion KRW | -28.69% |
| 2018 Q2 | -7.82 Billion KRW | -134.18% |
| 2017 FY | -13.86 Billion KRW | 27.51% |
| 2017 Q2 | -5.29 Billion KRW | -324.08% |
| 2017 Q3 | -4.72 Billion KRW | 10.63% |
| 2017 Q1 | -1.24 Billion KRW | 28.92% |
| 2017 Q4 | -2.59 Billion KRW | 45.1% |
| 2016 FY | -19.12 Billion KRW | -535.59% |
| 2016 Q2 | -451.47 Million KRW | 93.93% |
| 2016 Q3 | -9.48 Billion KRW | -1999.84% |
| 2016 Q4 | -1.75 Billion KRW | 81.48% |
| 2016 Q1 | -7.43 Billion KRW | -239.63% |
| 2015 Q1 | -961.85 Million KRW | 20.29% |
| 2015 Q4 | -2.19 Billion KRW | -302.83% |
| 2015 Q3 | 1.07 Billion KRW | 215.27% |
| 2015 FY | -3 Billion KRW | -72.04% |
| 2015 Q2 | -936.87 Million KRW | 2.6% |
| 2014 Q3 | -663.06 Million KRW | -323.18% |
| 2014 Q1 | -176.49 Million KRW | 96.86% |
| 2014 FY | -1.74 Billion KRW | 81.69% |
| 2014 Q2 | 297.09 Million KRW | 268.34% |
| 2014 Q4 | -1.2 Billion KRW | -81.99% |
| 2013 Q2 | -2.22 Billion KRW | -133.6% |
| 2013 FY | -9.55 Billion KRW | -1186.78% |
| 2013 Q4 | -5.62 Billion KRW | -660.8% |
| 2013 Q3 | -739.87 Million KRW | 66.79% |
| 2013 Q1 | -953.8 Million KRW | 8.65% |
| 2012 FY | 878.81 Million KRW | 108.29% |
| 2012 Q2 | 76.05 Million KRW | -82.68% |
| 2012 Q3 | 1.4 Billion KRW | 1750.69% |
| 2012 Q4 | -1.04 Billion KRW | -174.18% |
| 2012 Q1 | 439.25 Million KRW | 0.0% |
| 2011 Q3 | 203.68 Million KRW | 101.95% |
| 2011 Q2 | -10.42 Billion KRW | -4241.64% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q1 | 251.74 Million KRW | 0.0% |
| 2011 FY | -10.6 Billion KRW | -360.71% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 82.67 Million KRW | 0.0% |
| 2010 Q2 | -783.1 Million KRW | -1047.17% |
| 2010 Q3 | 7.65 Billion KRW | 1077.56% |
| 2010 FY | 4.06 Billion KRW | 801.26% |
| 2009 Q1 | 419.08 Million KRW | 0.0% |
| 2009 Q2 | 2.33 Billion KRW | 457.3% |
| 2009 Q3 | -1.17 Billion KRW | -150.22% |
| 2009 Q4 | - KRW | 100.0% |
| 2009 FY | -579.88 Million KRW | 6.9% |
| 2008 Q1 | 569.61 Million KRW | 0.0% |
| 2008 Q3 | 13.05 Million KRW | -88.91% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | -622.87 Million KRW | 86.33% |
| 2008 Q2 | 117.78 Million KRW | -79.32% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | -4.55 Billion KRW | -965.01% |
| 2007 Q1 | -1.95 Billion KRW | 0.0% |
| 2007 Q3 | 449.06 Million KRW | 113.28% |
| 2007 Q2 | -3.38 Billion KRW | -72.99% |
| 2006 FY | 526.73 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Green Cross Holdings Corporation | -54.13 Billion KRW | 123.775% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | 148.33% |
| Pharmicell Co., Ltd. | 3.57 Billion KRW | -259.729% |
| Green Cross Corporation | -26.63 Billion KRW | 148.33% |
| GeneOne Life Science, Inc. | -77.76 Billion KRW | 116.551% |
| Celltrion, Inc. | 535.64 Billion KRW | 97.597% |
| Samsung Biologics Co.,Ltd. | 857.69 Billion KRW | 98.499% |
| SK bioscience Co.,Ltd. | 22.31 Billion KRW | 42.328% |
| SK Biopharmaceuticals Co., Ltd. | -32.88 Billion KRW | 139.142% |
| Prestige BioPharma Limited | -32.92 Billion KRW | 139.097% |